全文获取类型
收费全文 | 345878篇 |
免费 | 30783篇 |
国内免费 | 10614篇 |
专业分类
耳鼻咽喉 | 2454篇 |
儿科学 | 6736篇 |
妇产科学 | 5462篇 |
基础医学 | 56325篇 |
口腔科学 | 6807篇 |
临床医学 | 23097篇 |
内科学 | 51073篇 |
皮肤病学 | 5184篇 |
神经病学 | 26061篇 |
特种医学 | 9644篇 |
外国民族医学 | 58篇 |
外科学 | 27258篇 |
综合类 | 45540篇 |
现状与发展 | 47篇 |
一般理论 | 8篇 |
预防医学 | 21581篇 |
眼科学 | 4298篇 |
药学 | 46140篇 |
71篇 | |
中国医学 | 17983篇 |
肿瘤学 | 31448篇 |
出版年
2024年 | 276篇 |
2023年 | 4751篇 |
2022年 | 6393篇 |
2021年 | 13281篇 |
2020年 | 12112篇 |
2019年 | 12947篇 |
2018年 | 12676篇 |
2017年 | 13174篇 |
2016年 | 13136篇 |
2015年 | 14053篇 |
2014年 | 17858篇 |
2013年 | 22887篇 |
2012年 | 19767篇 |
2011年 | 23561篇 |
2010年 | 17837篇 |
2009年 | 17473篇 |
2008年 | 18373篇 |
2007年 | 18187篇 |
2006年 | 16905篇 |
2005年 | 14925篇 |
2004年 | 12969篇 |
2003年 | 11262篇 |
2002年 | 8781篇 |
2001年 | 7763篇 |
2000年 | 6438篇 |
1999年 | 5446篇 |
1998年 | 4113篇 |
1997年 | 4039篇 |
1996年 | 3549篇 |
1995年 | 3422篇 |
1994年 | 3187篇 |
1993年 | 2660篇 |
1992年 | 2325篇 |
1991年 | 2156篇 |
1990年 | 1826篇 |
1989年 | 1497篇 |
1988年 | 1389篇 |
1987年 | 1218篇 |
1986年 | 1170篇 |
1985年 | 1872篇 |
1984年 | 1671篇 |
1983年 | 1192篇 |
1982年 | 1299篇 |
1981年 | 1061篇 |
1980年 | 927篇 |
1979年 | 803篇 |
1978年 | 558篇 |
1977年 | 449篇 |
1976年 | 424篇 |
1975年 | 313篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
2.
3.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
4.
5.
6.
7.
Mixed lineage leukemia 1(MLL1)是组蛋白甲基转移酶SET家族的成员之一。MLL1与WDR5、RbBP5、Ash2L和DPY-30组成MLL1甲基转移酶复合物调控组蛋白H3的第4位赖氨酸的甲基化水平,对造血系统的发育和血细胞的更新至关重要。部分白血病患者体内存在因MLL1基因易位而产生的致癌蛋白——MLL1融合蛋白,MLL1融合蛋白在发挥其致癌作用时需要功能完整的MLL1酶复合物,故靶向MLL1-WDR5的蛋白-蛋白相互作用成为治疗MLL1融合型白血病的潜在策略。本文对MLL1-WDR5蛋白-蛋白相互作用的生物学机制、结构信息以及抑制剂进行了系统的总结,并结合已报道数据对该领域进行了展望,以期为后续研究提供参考。 相似文献
8.
《Radiography》2022,28(2):353-359
Patient contact shielding has been in use for many years in radiology departments in order to reduce the effects and risks of ionising radiation on certain organs. New technologies in projection imaging and CT scanning such as digital receptors and automatic exposure control (AEC) systems have reduced doses and improved image consistency. These changes and a greater understanding of both the benefits and the risks from the use of shielding have led to a review of shielding use in radiology. A number of professional bodies have already issued guidance in this regard. This paper represents the current consensus view of the main bodies involved in radiation safety and imaging in Europe: European Federation of Organisations for Medical Physics, European Federation of Radiographer Societies, European Society of Radiology, European Society of Paediatric Radiology, EuroSafe Imaging, European Radiation Dosimetry Group (EURADOS), and European Academy of DentoMaxilloFacial Radiology (EADMFR). It is based on the expert recommendations of the Gonad and Patient Shielding (GAPS) Group formed with the purpose of developing consensus in this area. The recommendations are intended to be clear and easy to use. They are intended as guidance, and they are developed using a multidisciplinary team approach. It is recognised that regulations, custom and practice vary widely on the use of patient shielding in Europe and it is hoped that these recommendations will inform a change management program that will benefit patients and staff. 相似文献
9.
目的:探索嘌呤能受体X1(purinergic receptor,P2RX1)与肺腺癌(LUAD)患者预后及免疫细胞浸润的相关性。方法:利用生物信息学技术分析非小细胞肺癌中P2RX1的表达及其甲基化与患者预后的关系,对P2RX1共表达基因进行富集分析并筛选核心基因。利用TIMER 2.0数据库、R软件等分析P2RX1与免疫细胞、免疫检查点、免疫基质评分等的相关性。结果:P2RX1在LUAD中表达下调,低表达P2RX1的患者预后较差(P<0.05),且P2RX1与肿瘤纯度、分期等临床病理因素有关(P<0.05)。P2RX1的表达与肺鳞癌患者预后无明显相关。Cg06475633等P2RX1 CpG位点甲基化与患者预后相关。P2RX1共表达基因主要富集于免疫细胞活化、分化等通路和生物学进程,核心基因主要包括BTK、IKZF1等。P2RX1的表达与B细胞浸润、免疫/基质评分、PD-1、CTLA-4等多个免疫检查点显著相关(P<0.05)。结论:P2RX1有望成为LUAD诊断和免疫治疗的新靶点。 相似文献
10.